US FDA Hearing To Focus On Scientific Standards For Biosimilar, Interchangeable Insulins
US FDA will use May 13 hearing to gather input about scientific considerations and patient experience as it prepares for the submission and review of biosimilar and interchangeable applications after insulin products transition to biologics in March 2020.
